Big-ticket investors including Hong Kong-based alternative investment firm PAG and China Venture Capital Fund (CVC) have invested in the $100-million Series A funding round for biopharma firm Alphamab Oncology, according to a company announcement.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
